October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte

Integral service around a transaction
BY : Diego GutiérrezNovember Tue, 2015

In the second half of October we have witnessed that two Spanish companies focused on cancer treatment solutions have received funding. In addition, the largest deal in Crowdequity for the biotech sector has also been closed. The protagonist of this operation has been Mind The byte.



InnoUp Farma closes a €2M round

InnoUp Pharma which applies nanoparticle technology to oral drugs with the aim of reducing toxicity in cancer patients, has closed a €2M round.

Participating in the round were Sodena, Inveready and the Ministry of Economy and Competitiveness.

The round aims to complete the regulatory preclinical development of one of the leading intravenous anticancer drugs targeted at metastatic breast cancer.

InnoUp is already looking to the future and expects in less than two years to attract interest from other investors for further development and the securing of a relevant licensing agreement.

 In June 2015, the company won the Entrepreneur XXI award, being recognised as the most successful company in the Navarrese company with the greatest growth potential in Spain. 

Oryzon increases capital by €16.5M

Oryzon, which specialises in the development of therapies in oncology and neurodegenerative diseases, has announced that it has closed a capital increase 16.5M as a prelude to its IPO.

The objective of this round is to reinforce its research projects and to continue its international presence, in order to be able to go public on the MAB.

Among the new shareholders joining the firm are Joseph Fernández, CEO of Active Motif, a US firm specialising in epigenetics, and founder of Invitrogen, with 1.03% of the capital, and the MAB Capital Fund of the Institut Català de Finances (ICF).

Mind the byte closes the largest crowdequity round in the biotech sector in Spain

Specialised in computational drug design services, the Catalan company Mind The Byte has closed a €234,310 round through the crowdequity platform. Crowdcube.

This figure is more than double the budget the company had set as a target at the start of the campaign.

115 private investors participated in the round. The average investment was 2,037 eurosThe maximum investment was 80,000 euros.

The capital will be used to consolidate the company's expansion and internationalisation plan. Mind the Byte for which it has had the strategic support of ACCIÓ, of the Generalitat de Catalunya. The first step has been the opening of a subsidiary in the Copenhagen Bio Science Park, in one of the most dynamic European clusters in scientific innovation and technology transfer. The second will be "to promote the commercialisation of our pay-per-use Drug Discovery SaaS platform in countries such as the United States, Denmark, Germany and Japan," says Dr. Alfons Nonell-Canals, founder and CEO of Mind the Byte.

If you are looking for funding for your biotech company, contact us. Abra-Invest has a team of experts in financing in the sector. Fill in the contact form or call us on +34 946424142.

Other posts that may interest you

Biotech sector operations: Minoryx, Suanfarma, Ability Pharma and Oryzon

Biotech sector operations: Minoryx, Suanfarma, AbilitSpanish biotechs go international: Artax Biopharma, PharmaMar and Mind They Pharma and Oryzon

Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri Biotech


The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?